Best Hospitals for Atherosclerosis Treatment in Bengaluru, India

Atherosclerosis is a chronic, systemic inflammatory disease of medium and large arteries in which subendothelial deposition of oxidized low-density lipoprotein (LDL) cholesterol triggers a cascade of monocyte recruitment, foam cell formation, and smooth muscle proliferation. Over decades, these lipid-laden plaques calcify and may develop a vulnerable fibrous cap prone to rupture. When plaque ruptures, superimposed thrombosis acutely occludes the artery, producing acute coronary syndromes (ACS), ischemic stroke, or acute limb ischemia depending on the arterial territory involved. Risk amplifiers include dyslipidemia, hypertension, type 2 diabetes mellitus, chronic kidney disease, tobacco use, and inherited hyperlipidemias such as familial hypercholesterolemia (FH).

• ELIGIBLE PATIENTS:
• Patients with stable angina or silent ischemia with angiographically confirmed coronary stenosis >70% (or FFR ≤0.80) unresponsive to optimal medical therapy
• Patients with acute coronary syndrome (NSTEMI or STEMI) requiring urgent PCI or emergent CABG
• Patients with symptomatic carotid stenosis ≥50% (symptomatic) or ≥70% (asymptomatic) per NASCET criteria, eligible for carotid endarterectomy (CEA) or carotid artery stenting (CAS)
• Patients with peripheral arterial disease (PAD) and claudication, rest pain, or CLTI (Rutherford category 3–6) with suitable vascular anatomy for endovascular or open surgical revascularization
• +20 more

PHARMACOLOGICAL MANAGEMENT (Foundation of All Strategies): High-intensity statin therapy (atorvastatin 40–80 mg/day or rosuvastatin 20–40 mg/day) targets LDL-C reduction of ≥50% from baseline, aiming for LDL <55 mg/dL in very-high-risk patients per ESC/ACC guidelines. PCSK9 inhibitors (evolocumab 140 mg SC every 2 weeks or alirocumab 75–150 mg SC every 2 weeks) achieve an additional 50–60% LDL reduction beyond maximally tolerated statin doses and are now standard for FH or post-ACS patients not at goal. Inclisiran (a siRNA targeting PCSK9) offers twice-yearly dosing and is increasingly available in both India and the UAE. Dual antiplatelet therapy (DAPT) with aspirin 75–100 mg plus a P2Y12 inhibitor (ticagrelor 90 mg BID or clopidogrel 75 mg/day) is mandatory post-ACS and post-PCI for 6–12 months. In diabetic patients with established cardiovascular disease, GLP-1 RAs (semaglutide, liraglutide) and SGLT-2 inhibitors (dapagliflozin, empagliflozin) confer independent cardiovascular mortality benefits beyond glycemic control and are incorporated into GDMT.

PERCUTANEOUS CORONARY INTERVENTION (PCI) — Catheter-Based Coronary Revascularization: PCI remains the dominant revascularization strategy for single- and two-vessel coronary disease. Under fluoroscopic and IVUS/OCT guidance, a guide catheter is advanced to the coronary ostium, a 0.014-inch guidewire crosses the stenosis, and the lesion is treated with balloon angioplasty followed by deployment of a Drug-Eluting Stent (DES). Contemporary third-generation DES platforms (Xience Sierra, Synergy bioabsorbable-polymer, Orsiro sirolimus-eluting stent) achieve restenosis rates of <5% at 1 year. Calcified lesions refractory to standard balloon angioplasty are treated with Rotational Atherectomy (Rotablator) or Intravascular Lithotripsy (IVL, Shockwave system) to facilitate stent expansion. For chronic total occlusions (CTO), complex retrograde or antegrade wire escalation techniques are employed by dedicated CTO operators. Fractional Flow Reserve-guided PCI (FFR-guided) is the benchmark standard, avoiding stenting of non-flow-limiting lesions and demonstrably reducing MACE.

CABG — CORONARY ARTERY BYPASS GRAFTING (Surgical Gold Standard for Complex Disease): For patients with three-vessel disease, left main coronary disease, or high SYNTAX Score (>32), CABG provides superior long-term survival and freedom from re-intervention compared to PCI. The procedure uses arterial conduits—Left Internal Mammary Artery (LIMA) anastomosed to the LAD is the cornerstone, with additional grafts using the Right Internal Mammary Artery (RIMA), radial artery, or saphenous vein. Total Arterial Revascularization (TAR) strategies using bilateral mammary arteries improve 10-year patency. Off-Pump CABG (OPCAB) is performed on the beating heart without cardiopulmonary bypass, reducing the risks of cognitive dysfunction, stroke, and renal injury in selected patients. Minimally invasive CABG variants include MIDCAB (Minimally Invasive Direct CABG via mini-thoracotomy) and Totally Endoscopic CABG (TECAB) using robotic assistance (da Vinci Surgical System), both reducing sternal complications and recovery time.

CAROTID REVASCULARIZATION: Carotid Endarterectomy (CEA) remains the gold-standard surgical procedure for significant carotid atherosclerosis, involving surgical plaque excision under regional or general anesthesia with excellent long-term stroke prevention. Carotid Artery Stenting (CAS) with cerebral embolic protection devices (EPDs) is the catheter-based alternative for high-surgical-risk patients. Transcarotid Artery Revascularization (TCAR) combines surgical carotid access with flow reversal and stenting, demonstrating stroke rates comparable to CEA in contemporary registry data.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel):

Patients upload existing medical records, imaging (angiograms, echocardiograms, CT scans), and lab reports to the GAF Healthcare secure patient portal. A GAF-coordinated multidisciplinary team (interventional cardiologist, vascular surgeon, cardiac surgeon) conducts a virtual consultation, reviews diagnostic findings, and proposes a personalized treatment pathway. A formal medical opinion letter, itemized cost estimate, and hospital admission protocol are provided within 48–72 hours. GAF Healthcare initiates e-Medical Visa processing for India or entry documentation for the UAE simultaneously.

PHASE 2 — ARRIVAL & IN-HOSPITAL DIAGNOSTIC WORKUP (Day 1–3):